Patents by Inventor Jin-Long Chen

Jin-Long Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5846779
    Abstract: The invention provides methods and compositions relating to a novel family of genes, mUCP3s, involved in metabolic regulation. The polypeptides may be produced recombinantly from transformed host cells from the disclosed mUCP3 encoding nucleic acids or purified from mammalian cells. The invention provides isolated mUCP3 hybridization probes, knock-out/in constructs and primers capable of specifically hybridizing with the disclosed mUCP3 genes, mUCP3-specific binding agents such as specific antibodies, animals and cells modified with the subject mUCP3 nucleic acids, and methods of making and using the subject compositions in the biopharmaceutical industry.
    Type: Grant
    Filed: September 25, 1997
    Date of Patent: December 8, 1998
    Assignee: Tularik Inc.
    Inventors: Ning Zhang, M. Catherine Amaral, Jin-Long Chen
  • Patent number: 5807740
    Abstract: The invention relates to regulators of UCP2 gene transcription, including novel UCP2 transcriptional promoters. UCP2 gene promoters are used in diagnosis and pharmaceutical development. In particular, transfected cells comprising UCP2 gene promoters operably linked to a reporter are used in high-throughput pharmaceutical screens.
    Type: Grant
    Filed: April 25, 1997
    Date of Patent: September 15, 1998
    Assignee: Tularik Inc.
    Inventors: M. Catherine Amaral, Jin-Long Chen
  • Patent number: 5780258
    Abstract: The invention provides methods and compositions for screening for pharmacological agents which regulate satiety, fat metabolism and/or the type II diabetes mellitus in mammals, and in particular, agents active at regulating the level of ob gene expression. An exemplary assay involves (a) contacting a mammalian adipocyte comprising a mutant of a native ob allele encoding a reporter of ob gene expression, wherein the expression of the reporter is under the control of the gene expression regulatory sequences of the native ob allele, with a candidate agent under conditions whereby but for the presence of the agent, the reporter is expressed at a first expression level; and, (b) measuring the expression of the reporter to obtain a second expression level, wherein a difference between the first and second expression levels indicates that the candidate agent modulates ob gene expression.
    Type: Grant
    Filed: September 4, 1996
    Date of Patent: July 14, 1998
    Assignee: Tularik, Inc
    Inventors: Fabienne Charles de la Brousse, Jin-long Chen
  • Patent number: 5698389
    Abstract: The invention relates to the Ob gene transcriptional promoter. The subject promoters generally comprise a C/EBP binding site and a novel untranslated Ob gene exon. Ob gene promoters are used in diagnosis and pharmaceutical development. In particular, transfected adipocytes comprising Ob gene promoters operably linked to a reporter are used in high-throughput pharmaceutical screens.
    Type: Grant
    Filed: November 16, 1995
    Date of Patent: December 16, 1997
    Assignee: Tularik, Inc.
    Inventors: Fabienne Charles de la Brousse, Jin-long Chen